Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 1222

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 1222
---
 financial reporting or an attestation report of our
independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.

Changes in Internal Control Over Financial
Reporting

There were no changes in our
internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fourth
quarter of the fiscal year covered by this annual report that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION.

None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS.

Not applicable.

16

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE.

Directors and Executive Officers

Our directors and executive
officers are as follows:

    Name
     
    Age
     
    Title
  
    Lynn Stockwell
     
    69
     
    Chief Executive Officer and Executive Chair of the Board
  
    Glenn Worman
     
    66
     
    Chief Financial Officer
  
    Catherine Do
     
    45
     
    Director 
  
    G. Sridhar Prasad
     
    62
     
    Director 
  
    Myron W. Shulgan
     
    79
     
    Director 

Lynn Stockwell has been our Chief Executive
Officer since September 2024 and Executive Chair of the Board since June 2024 and is the managing member of the sponsor. Ms. Stockwell
is the founder of Bright Green Corporation (Nasdaq: BGXX), where she has been a board member since its inception in 2019 and Chair of
the Board since February 2024. From 2015 to 2020, Ms. Stockwell was Managing Member of Bright Green Innovations, LLC, a pioneering
plant-based pharmaceutical research company recognized for its compliance with federal legal standards. In this role, Ms. Stockwell expertly
managed business, industry, and medical research relationships. In addition to her leadership roles, Ms. Stockwell has also served as
a director at a hospital, where she spearheaded fundraising initiatives advocating for the use of natural additives as a safer alternative
to opioids. Her dedica tion extends to her sponsorship of biomedical research and clinical trials